The pandemic left many GPs around the world feeling depressed, anxious and in some cases burned out, a review of global studies has revealed.

First manufactured more than 50 years ago, ketamine is a fast-acting dissociative anesthetic often used in veterinary and emergency medicine. Ketamine also has a history of being an illicit party drug. Now, ketamine is getting a closer look.

Researchers have discovered a small group of brain cells in the claustrum that controls stress-induced anxiety behaviors. Manipulating the activity of these cells also altered anxiety-related behaviors, which suggested that these claustrum cells are key to the pathogenesis of stress-related mental disorders. Furthermore, this group of cells may be considered a new target for the treatment of stress-related conditions.

As Oregon embarks on a voter-approved initiative to permit psychoactive mushrooms in clinical use, a new systematic evidence review reveals a lack of scientific research describing the interactions between widely used psychiatric medications and psychedelics like psilocybin and MDMA.

A new study shows that using cannabis products to treat pain, anxiety and depression failed to improve these symptoms while doubling the risk of developing the addictive symptoms of cannabis use disorder. People seeking cannabis to treat symptoms of anxiety and depression were at greatest risk of CUD. Contrary to evidence-based medicine, people with medical marijuana cards choose their own products and dosing, suggesting the need for better controls over dispensing, use, and professional follow-up of these patients.

Researchers have identified a link suggesting that lithium could decrease the risk of developing dementia, which affects nearly one million people in the UK.

Psychedelics may find new, legitimate roles in treatment for anxiety, depression, stress disorders, addiction, and other mental and behavioral health problems. But ensuring they do requires developing rigorous, standardized methods to study and apply the results, according to a new report.

Researchers have taken the first step in using artificial intelligence (AI) to predict early outcomes with antidepressants in children and adolescents with major depressive disorder.

One in three new mothers during early COVID-19 screened positive for postpartum depression -- nearly triple pre-pandemic levels -- and 1 in 5 had major depressive symptoms, say researchers.

Exposure to ozone from air pollution has been linked to an increase in depressive symptoms for adolescents over time, even in neighborhoods that meet air quality standards, according to new research.